Pacific Edge Limited logo

Director Change: Resignation of John Duncan

Director Departure2 October 2019PEBHealthcare

Company Announcement
2 October 2019



DIRECTOR CHANGE: RESIGNATION OF JOHN DUNCAN


Pacific Edge Limited advises that John Duncan has notified the Board of his resignation as a Director of the company,

effective immediately.


The Board thanks John for his service and wishes him well. John remains a supportive shareholder in the company.


ENDS



For more information contact:


Chris Gallaher

Chairman

Pacific Edge Ltd

P: +61 417 556 691



OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and

commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of

non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management

of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally

through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and

validated in international multi-centre clinical studies.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.